Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 4:2021:8845129.
doi: 10.1155/2021/8845129. eCollection 2021.

Effects of Remimazolam and Propofol on Ca2+ Regulation by Ryanodine Receptor 1 with Malignant Hyperthermia Mutation

Affiliations

Effects of Remimazolam and Propofol on Ca2+ Regulation by Ryanodine Receptor 1 with Malignant Hyperthermia Mutation

Tomoyuki Watanabe et al. Biomed Res Int. .

Abstract

Background: We investigated the potential safety of remimazolam and propofol in malignant hyperthermia- (HM-) susceptible patients using ryanodine receptor 1- (RYR1-) expressing human embryonic kidney- (HEK-) 293 cells.

Methods: We compared the enhanced responsiveness of HEK-293 cells expressing wild-type RYR1 with that of mutant RYR1 to caffeine following perfusion with remimazolam or propofol. Furthermore, we investigated whether RYR1 enhanced the responsiveness of cells to remimazolam or propofol and compared the median effective concentration (EC50; i.e., the concentration required to reach half-maximal activation) using an unpaired two-tailed t-test while a P < 0.05 was considered significant.

Results: Remimazolam and propofol did not promote the caffeine-induced increase in intracellular Ca2+ levels in HEK-293 cells expressing mutant RYR1 even with exposure to approximately 100-fold the clinically used concentration. In wild-type RYR1, EC50 values of remimazolam following refusion vs. nonperfusion were 2.86 mM vs. 2.75 mM (P = 0.76) while for propofol perfusion vs. nonperfusion, they were 2.76 mM vs. 2.75 mM, respectively (P = 0.83). In mutant RYR1, EC50 values of remimazolam refusion vs. nonperfusion were 1.58 mM vs. 1.71 mM, respectively (P = 0.63) while for propofol perfusion vs. nonperfusion, they were 1.65 mM vs. 1.71 mM, respectively (P = 0.73). Remimazolam and propofol increased intracellular Ca2+ levels in a concentration-dependent manner, but the effect was not enhanced by RYR1. EC50 values of remimazolam with non-RYR1 vs. wild-type RYR1 were 1.00 mM vs. 0.92 mM, respectively (P = 0.91) while those of propofol were 1.09 mM vs. 1.05 mM, respectively (P = 0.84).

Conclusions: The increase in intracellular Ca2+ concentration caused by remimazolam or propofol was not considered an RYR1-mediated reaction. We conclude that remimazolam and propofol can be safely used as an anesthetic in MH-susceptible patients with RYR1-mutation without causing MH and may be safely substituted for an MH-triggering anesthetic when RYR1-mediated MH occurs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1
Western blot image. Western blot image confirmed the presence of ryanodine receptor 1 (RYR1) protein in the human embryonic kidney- (HEK-) 293 cells transfected with wild-type or mutant RYR1, p.Thr84Met, p.Ser2345Arg, or p.Ala4894Thr.
Figure 2
Figure 2
Representative Ca2+ release response of wild-type ryanodine receptor 1- (RYR1-) transfected human embryonic kidney- (HEK-) 293 cells or non-RYR1-transfected HEK-293 cells. Representative traces of agonist-induced Ca2+ release by HEK-293 cells transfected with wild-type pcRYR1 cDNA or without any pcRYR1 cDNA. The vertical axis represents the Fura-2 ratio (340/380 nm), i.e., intracellular Ca2+ release, and the horizontal axis represents time (minutes). The response of wild-type RYR1 expressing HEK-293 cells to (a) caffeine, (b) caffeine with continuous reflux of remimazolam (546 μM, 100-fold higher than clinical dose), (c) caffeine with continuous reflux of propofol (100 μM, 100-fold higher than the clinical dose), (d) remimazolam (increasing concentrations up to 5020 μM), and (e) propofol (increasing concentrations up to 5000 μM). The response of HEK-293 cells without expressing RYR1 to caffeine (f). No increase in intracellular Ca2+ levels for caffeine was observed in HEK-293 cells without expressing RYR1.
Figure 3
Figure 3
Caffeine concentration-dependent Ca2+ release in human embryonic kidney- (HEK-) 293 cells transfected with wild-type or mutant ryanodine receptor 1 (RYR1). Caffeine dose-response of Ca2+ release in HEK-293 cells transfected with wild-type or mutant RYR1. Data were normalized to the maximal response of each cell type. The vertical axis represents the percentage of maximal Ca2+ response, and the horizontal axis represents caffeine concentration (mM). Data are means ± SD in mutants and wild-type. Circles and other symbols represent the wild-type and mutant RYR1-transfected groups. The response of (a) wild-type RYR1 and p.Thr84Met RYR1-transfected cells, (b) wild-type RYR1 and p.Ser2345Arg RYR1-transfected cells, and (c) wild-type RYR1 and p.Ala4894Thr RYR1-transfected cells to caffeine. Curves of all mutant RYR1-transfected cells were shifted leftward relative to those of wild-type RYR1-transfected cells.
Figure 4
Figure 4
Caffeine concentration-dependent Ca2+ release in human embryonic kidney (HEK-293) cells transfected with wild-type or mutant ryanodine receptor 1 (RYR1) perfused with remimazolam or propofol. Caffeine-induced Ca2+ release in HEK-293 cells transfected with wild-type or mutant RYR1 perfused with remimazolam or propofol. Data were normalized to the maximal response of each cell type. Vertical and horizontal axes represent percentage maximal Ca2+ response and caffeine concentration (mM). Data are means ± SD in cells perfused with or without remimazolam or propofol. Squares and circles represent remimazolam or propofol perfusion and nonperfused groups, respectively. (a–d) Remimazolam and (e–h) propofol perfused cells. Response of (a) wild-type, (b) p.Thr84Met, (c) p.Ser2345Arg, (d) p.Ala4894Thr, (e) wild-type, (f) p.Thr84Met RYR1, (g) p.Ser2345Arg, and (h) p.Ala4894Thr. Curves of all mutant and wild-type RYR1-transfected cells did not show a clear leftward shift under perfusion of remimazolam or propofol.
Figure 5
Figure 5
Remimazolam and propofol concentration-dependent Ca2+ release by human embryonic kidney- (HEK-) 293 cells transfected with or without wild-type ryanodine receptor 1 (RYR1). Remimazolam and propofol concentration-response curves of RYR1-untransfected cells and wild-type RYR1-transfected cells are shown. Data were normalized to the maximal response of each cell type. The vertical axis represents percentage maximal Ca2+ response, and the horizontal axis represents remimazolam or propofol concentration (mM). Data are means ± SD in nontransfected and wild-type RYR1. Circles and squares represent wild-type RYR1 and untransfected groups, respectively. Dose-response curves of (a) remimazolam and (b) propofol. Curves showed no significant leftward shift in wild-type RYR1-transfected cells compared to untransfected RYR1 cells.

References

    1. Denborough M., Lovell R. R. H. Anaesthetic deaths in a family. Lancet. 1960;276(7140):p. 45. doi: 10.1016/s0140-6736(60)92690-8. - DOI - PubMed
    1. Denborough M. Malignant hyperthermia. Lancet. 1998;352(9134):1131–1136. doi: 10.1016/S0140-6736(98)03078-5. - DOI - PubMed
    1. Censier K., Urwyler A., Zorzato F., Treves S. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and arg163cys mutated ryanodine receptors. The Journal of Clinical Investigation. 1998;101(6):1233–1242. doi: 10.1172/JCI993. - DOI - PMC - PubMed
    1. Girard T., Treves S., Censier K., Mueller C. R., Zorzato F., Urwyler A. Phenotyping malignant hyperthermia susceptibility by measuring halothane- induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. British Journal of Anaesthesia. 2002;89(4):571–579. doi: 10.1093/bja/aef237. - DOI - PubMed
    1. Tuman K. J., Spiess B. D., Wong C. A., Ivankovich A. D. Sufentanil-midazolam anesthesia in malignant hyperthermia. Anesthesia and Analgesia. 1988;67(4):405–408. - PubMed

MeSH terms

LinkOut - more resources